Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Anti-Diabetes Drugs - APAC

APAC
  • Revenue in the Anti-Diabetes Drugs market is projected to reach US$17.91bn in 2024.
  • Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 5.68%, resulting in a market volume of US$22.34bn by 2028.
  • In global comparison, most revenue will be generated United States (US$37.84bn in 2024).

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

In-Scope

  • Drugs to treat diabetes mellitus (oral intake and injections)
  • Insulin
  • Non-insulinotropic anti-diabetic drugs

Out-Of-Scope

  • Drugs to treat other metabolic disorders or other autoimmune diseases
  • Lipid-lowering agents
  • Drugs to treat hypertension
  • Diagnostics
  • Devices such as continuous glucose monitors
Pharmaceuticals

Pharmaceuticals

Related markets:
Anti-Diabetes Drugs: market data & analysis - Cover

Market Insights report

Anti-Diabetes Drugs: market data & analysis

Study Details
    methodology

    Download PDF

    FAQs and more info on the methodology

    Revenue

    Notes: Data was converted from local currencies using average exchange rates of the respective year.

    Most recent update: Mar 2024

    Source: Statista Market Insights

    Analyst Opinion

    The Anti-Diabetes Drugs market is experiencing steady growth. This development is driven by the number of patients, which is projected to increase continuously over the next years. The majority of cases are type 2 diabetes, which is associated with obesity, and the number of obese people worldwide is projected to increase by a few percent every year. Additionally, the market is driven by an increasing awareness of health issues and by improving access to healthcare in emerging countries.

    At the beginning of the COVID-19 pandemic, there were stocking effects brought about by patients fearing a shortage of medications. This led to an increase in sales of some products, which, however, is not reflected in the annual revenue numbers as it was counterbalanced later in 2020. Instead, growth declined by some percentage points because fewer patients decided to seek treatment.

    Global Comparison

    Most recent update: Mar 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Anti-Diabetes Drugs: market data & analysis - BackgroundAnti-Diabetes Drugs: market data & analysis - Cover

    Explore more high-quality data on related topic

    Diabetes - Statistics & Facts

    In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.
    More data on the topic
    Number of diabetics worldwide
    537m
    Number of children worldwide with type 1 diabetes
    652,000
    Global health care expenditure to treat diabetes
    966bn USD

    Contact

    Get in touch with us. We are happy to help.